Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | VNN1 | O95497 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278755 | 0.78 | HPGD (0.47) | MAOAERCC1ERCC4VNN1MMP13 | |
| SCHEMBL21952006 | 0.78 | HPGD (0.47) | MAOAERCC1ERCC4VNN1MMP13 | |
| SCHEMBL22016322 | 0.69 | MAOA (0.40) | MAOAERCC1ERCC4ROCK2CHRM3 | |
| SCHEMBL21952060 | 0.64 | KMT2A (0.58) | — | |
| SCHEMBL31396269 | 0.64 | KMT2A (0.58) | — | |
| SCHEMBL27555758 | 0.63 | FFAR1 (0.49) | VNN1 | |
| SCHEMBL3461756 | 0.63 | ERCC1 (0.60) | MAOAERCC1ERCC4ROCK2VNN1 | |
| SCHEMBL13853501 | 0.62 | ERCC1 (0.56) | MAOAERCC1ERCC4ROCK2VNN1 | |
| SCHEMBL8645386 | 0.62 | ERCC1 (0.59) | MAOAERCC1ERCC4ROCK2ROCK1 | |
| SCHEMBL38654611 | 0.62 | ERCC1 (0.59) | MAOAERCC1ERCC4ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | NR3C2 4094/4885MAOA 2558/4885ERCC1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.